HK1213800A1 - 類毒素、組合物及相關方法 - Google Patents

類毒素、組合物及相關方法 Download PDF

Info

Publication number
HK1213800A1
HK1213800A1 HK16101854.5A HK16101854A HK1213800A1 HK 1213800 A1 HK1213800 A1 HK 1213800A1 HK 16101854 A HK16101854 A HK 16101854A HK 1213800 A1 HK1213800 A1 HK 1213800A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
toxoid
related methods
inactivating
Prior art date
Application number
HK16101854.5A
Other languages
English (en)
Chinese (zh)
Inventor
Steven HAUSER
Original Assignee
Sanofi Pasteur, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Inc. filed Critical Sanofi Pasteur, Inc.
Publication of HK1213800A1 publication Critical patent/HK1213800A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK16101854.5A 2013-03-15 2014-03-14 類毒素、組合物及相關方法 HK1213800A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
HK1213800A1 true HK1213800A1 (zh) 2016-07-15

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101854.5A HK1213800A1 (zh) 2013-03-15 2014-03-14 類毒素、組合物及相關方法

Country Status (13)

Country Link
US (2) US20160045586A1 (enExample)
EP (1) EP2968507A2 (enExample)
JP (1) JP2016516721A (enExample)
KR (1) KR20150133770A (enExample)
CN (1) CN105338997A (enExample)
AR (1) AR095669A1 (enExample)
AU (1) AU2014228956A1 (enExample)
BR (1) BR112015023332A2 (enExample)
CA (1) CA2907154A1 (enExample)
HK (1) HK1213800A1 (enExample)
SG (1) SG11201507608PA (enExample)
TW (1) TWI624474B (enExample)
WO (1) WO2014144567A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) * 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
AU2022408126A1 (en) * 2021-12-06 2024-07-04 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
DE69829400T2 (de) * 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
AU2008280755B9 (en) 2007-07-26 2014-09-25 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
SG11201507608PA (en) 2015-10-29
WO2014144567A2 (en) 2014-09-18
AR095669A1 (es) 2015-11-04
CA2907154A1 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
EP2968507A2 (en) 2016-01-20
AU2014228956A1 (en) 2015-10-08
BR112015023332A2 (pt) 2017-08-22
KR20150133770A (ko) 2015-11-30
TWI624474B (zh) 2018-05-21
JP2016516721A (ja) 2016-06-09
US20180028637A1 (en) 2018-02-01
US20160045586A1 (en) 2016-02-18
CN105338997A (zh) 2016-02-17
WO2014144567A3 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1213800A1 (zh) 類毒素、組合物及相關方法
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
AU2014241199A8 (en) Compositions and methods for enhancing plant growth
MX2011007983A (es) Composiciones de polimero que contienen absorbedores de ir nanoparticulas.
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2014201044A3 (en) Plant growth-promoting microorganisms and methods of use thereof
WO2013041975A3 (en) Pyrethroid formulations
MX361812B (es) Cubierta para ventilador de plástico y ensamble de cono y método.
WO2013006055A8 (en) A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
MX364712B (es) Composiciones sinergicas que comprenden etefona y saflufenacilo o ciclanilida y saflufenacilo.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
TN2015000477A1 (en) A new bacterial lysobacter capsici strain and uses thereof
HK1225744A1 (zh) 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
NZ709925A (en) Temperature stable cloquintocet-mexyl aqueous compositions
PH12014500175A1 (en) Maize plants having a partially or fully multiplied genome and uses thereof
PH12017501795A1 (en) Pestivirus vaccines for congenital tremors
MX2016000141A (es) El uso de piridonacarboxamidas seleccionadas o sales de las mismas como sustancias activas contra el estres abiotico de las plantas.
WO2014205355A3 (en) Compositions and methods for clostridial transformation
HK1213917A1 (zh) 類霉素、組合物及相關方法
WO2014009204A8 (de) Oxasilacyclen und verfahren zu deren herstellung
BR112012033213B8 (pt) Cassete de expressão, vetor incluindo um construto de arni e método de preparação de uma planta transgênica